2 terminated, 1 not yet recruiting, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Pentixapharm AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of [68Ga]Ga-PentixaFor PET Imaging for the Identification of Unilateral Adrenal Secretion of ALdosterON in Patients With Primary Aldosteronism [68Ga]Ga-PentixaFor PET imaging - Primary Aldosteronism | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 20 | 2024-06-01 | 2024-06-27 |
| [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose - Marginal Zone Lymphoma | Phase 3 | Terminated | Pentixapharm AG | 8 | 2024-05-20 | 2026-04-28 |
| [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients [90Y]Y-PentixaTher - CNS Lymphoma | Phase 1 / Phase 2 | Recruiting | Pentixapharm AG | 15 | 2023-11-07 | 2026-06-05 |
| [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients 68Ga-PTF - CNS Lymphoma | Phase 2 | Terminated | Pentixapharm AG | 1 | 2022-10-05 | 2025-09-05 |
Hyperaldosteronism (1) · Lymphoma, B-Cell, Marginal Zone (1)
68Ga-pentixafor (1) · Fluorodeoxyglucose F18 (1)
France (3) · Germany (2) · Austria (1) · Denmark (1) · Italy (1) · Spain (1)
Andreas Buck, Prof. Dr. (1) · Bastian von Tresckow, Prof. Dr. med. (1)
2023 (1)